GL1X · GenesisL1 explorer

MolNFT v1 · #86613 · protein

Discovery of a potent, selective and orally active PDE10A inhibitor for the treatment of schizophrenia

4BBX · Camp and camp-inhibited cgmp 3', 5'-cyclic…: “Discovery of a potent, selective and orally active PDE10A inhibitor for the treatment of schizophrenia”. X-ray diffraction, 3 ligands (LKF, ZN, MG), 8 pockets (best druggability 0.73).…

PDB
4BBX
Type
protein
Length
624 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Camp and camp-inhibited cgmp 3', 5'-cyclic phosphodiesterase 10A
EC
3.1.4.17, 3.1.4.35
UniProt
Q9Y233
Ligands
LKF, ZN, MG
Pockets
8 · best druggability 0.73

Structure

x-ray diffraction · 1 distinct chain · 73% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BCamp and camp-inhibited cgmp 3', 5'-cyclic phosphodiesterase 10A (EC 3.1.4.17, 3.1.4.35)protein31273% helix, 0% strandQ9Y233

Ligands and binding sites

  • LKF · 4-[3-[1-[(2S)-2-methoxypropyl]pyrazol-4-yl]-2-methyl-imidazo[1,2-a]pyrazin-8-yl]morpholine · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16170.730.8058LKF, MG
23990.710.8245LKF, MG
36130.690.7851empty
41050.560.8425empty
51030.390.7617empty

Interfaces

1 interface between chains.

  • A–B · 748 Ų buried · 6 hydrogen bonds · protein-protein

Compared structures

  • 4BBX · Discovery of a potent, selective and orally active PDE10A inhibitor for the treatment of… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.